華檢醫療(01931.HK):香港證監會對劉紹基展開研訊程序
格隆匯11月4日丨華檢醫療(01931.HK)發佈公告,公司從香港證監會於2019年10月31日發佈的新聞稿獲悉,證監會已於市場失當行為審裁處就中國網絡(00383.HK)展開研訊程序,指其沒有在合理地切實可行的範圍內,儘快披露內幕信息;及對六名在關鍵時間擔任中國網絡的董事(包括劉紹基)展開研訊程序,原因是彼等罔顧後果或疏忽的行為導致中國網絡涉嫌違規。
公司獲劉紹基告知,彼不同意證監會在研訊程序中對其的指控,擬對研訊程序進行嚴正抗辯。在此期間及直至研訊程序結束,研訊程序尚未作出與其有關的調查結論。由於研訊程序並不涉及集團,因此公司認為研訊程序不會對集團的業務及╱或經營造成任何重大不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.